China SXT Pharmaceuticals, Inc. (SXTC) stock
SXTCNasdaqPharmaceutical PreparationsFiscal year ends March 31
$3.00+0.27 (+9.89%)
Close on Nov 13, 2026Market cap $2.87MP/E –Yield –
China SXT Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
For fiscal 2026 it was -$7.05M. The highest annual figure on record is $1.95M in fiscal 2019.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | -$7.05M | – |
| FY2025 | Mar 31, 2025 | -$2.60M | – |
| FY2024 | Mar 31, 2024 | -$2.31M | – |
| FY2023 | Mar 31, 2023 | -$5.36M | – |
| FY2022 | Mar 31, 2022 | -$4.87M | – |
| FY2021 | Mar 31, 2021 | -$1.85M | – |
| FY2020 | Mar 31, 2020 | -$1.01M | -151.7% |
| FY2019 | Mar 31, 2019 | $1.95M | +10.7% |
| FY2018 | Mar 31, 2018 | $1.76M | – |
See a number that looks wrong?